SVB Securities analyst Roanna Ruiz reiterated a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) on September 7. The company’s shares closed last Friday at $1.82.
Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Myovant Sciences, and scPharmaceuticals. According to TipRanks, Ruiz has an average return of -46.7% and a 15.79% success rate on recommended stocks.
Xeris Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.17 and a one-year low of $1.25. Currently, Xeris Pharmaceuticals has an average volume of 1.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
- Kepler Capital Keeps Their Buy Rating on Siemens Energy (SMEGF)
- New Buy Rating for Corteva (CTVA), the Basic Materials Giant
- Analysts Are Bullish on Top Financial Stocks: Hippo Holdings (HIPO), State Street (STT)
- Analysts Offer Insights on Services Companies: Six Flags (SIX) and Copart (CPRT)
- Analysts Offer Insights on Technology Companies: Phreesia (PHR), Boeing (BA) and Snap (SNAP)
